|
KMID : 0311120080490050775
|
|
Yonsei Medical Journal
2008 Volume.49 No. 5 p.775 ~ p.782
|
|
|
Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer:Comparative Analysis between 1st-line and 2nd-line Docetaxel
|
|
Jeong Jae-Young
Jeong In-Gab
Han Kyung-Seok
Yang Seung-Ok
Seo Ho-Kyung
Chung Jin-soo
Lee Kang-Hyun
Kim Taek-Sang
Cho Kang-Su
|
|
|
Abstract
|
|
|
Purpose: This study was undertaken to investigate the outcomes associated with docetaxel treatment of Korean patients with hormone-refractory prostate cancer (HRPC) and to compare its clinical efficacies in 1st and 2nd-line settings.
Patients and Methods: This study was retrospectively performed and included 47 patients with HRPC. The 1st-line group consisted of 19 patients who had not undergone prior chemotherapy, and the 2nd-line group consisted of 28 patients who underwent prior chemotherapy. All patients were treated with 75mg/m2 IV docetaxel every 3 weeks and 5mg of prednisone twice daily with a continuous androgen blockade.
Results: Of 47 study subjects, 14 patients (29.8%) had ≥ 50% PSA decline from baseline. PSA response was more common in the 1st-line group, but this was not statistically different (42.1% vs. 21.4%, p = 0.114). After a median follow up of 11 months (range, 6-24 months), the 1st-line group showed a longer time to PSA progression (4 vs. 2 months, p = 0.015) and survival (17 vs. 10 months, p = 0.037) than the 2nd-line group. In terms of toxicities, no difference was apparent between the 2 groups.
Conclusion: In a 1st-line setting, docetaxel is an effective and tolerable agent for Korean HRPC patients, and that its efficacy is limited, although 2nd-line docetaxel is tolerable.
|
|
|
KEYWORD
|
|
|
Prostate neoplasm, chemotherapy, docetaxel
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
   
|
|